等待开盘 03-27 09:30:00 美东时间
-0.040
-2.80%
Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.33) by 12.65 percent. This is a 50.85 percent increase over losses of $(0.59) per share from
03-23 19:12
Pyxis Oncology released preliminary data from Phase 1 studies of MICVO for recurrent/metastatic head and neck squamous cell carcinoma.
2025-12-19 22:07
U.S. stocks traded higher this morning, with the Dow Jones index gaining around...
2025-12-18 22:47
RBC Capital analyst Leonid Timashev reiterates Pyxis Oncology (NASDAQ:PYXS) with a Outperform and maintains $7 price target.
2024-09-19 21:55